GLP-1 receptor agonists, the science behind Ozempic and its cousins, have become one of the most talked-about medical breakthroughs of the past decade, reshaping how the world thinks about diabetes and obesity. The numbers are extraordinary, the headlines relentless and the share prices of the companies making them have reflected both.